Bioventus Inc. (NYSE:BVS) SVP Sells $66,038.72 in Stock

Bioventus Inc. (NYSE:BVS) SVP Anthony D’adamio sold 11,308 shares of Bioventus stock in a transaction dated Monday, June 17th. The stock was sold at an average price of $5.84, for a total transaction of $66,038.72. Following the transaction, the senior vice president now directly owns 81,630 shares in the company, valued at $476,719.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Anthony D’adamio also recently made the following trade(s):

• On Thursday, April 11th, Anthony D’adamio sold 3,054 shares of Bioventus stock. The shares were sold at an average price of $4.75, for a total transaction of $14,506.50.

Bioventus Stock Up 1.3 %

NYSE:BVS opened at $5.67 on Monday. Bioventus Inc. has a 52 week low of $2.70 and a 52 week high of $7.04. The company has a quick ratio of 0.97, a current ratio of 1.53 and a debt-to-equity ratio of 1.63. The stock’s fifty day moving average is $5.60 and its two-hundred day moving average is $5.17. The stock has a market capitalization of $448.89 million, a price-to-earnings ratio of -16.20 and a beta of 0.89.

Bioventus (NYSE:BVS) last posted its earnings results on Tuesday, May 7th. The company reported $0.07 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.12. The firm had revenue of $129.46 million for the quarter, compared to analyst estimates of $115.51 million. Bioventus had a positive return on equity of 11.91% and a negative net margin of 4.14%. Research analysts anticipate that Bioventus Inc. will post 0.27 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. Canaccord Genuity Group lifted their target price on Bioventus from $7.00 to $8.00 and gave the company a “buy” rating in a research report on Wednesday, May 8th. Craig Hallum upped their target price on shares of Bioventus from $6.00 to $9.00 and gave the company a “buy” rating in a research report on Wednesday, March 13th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in BVS. Kennedy Capital Management LLC purchased a new position in Bioventus in the 3rd quarter valued at approximately $220,000. Barclays PLC purchased a new position in Bioventus in the third quarter valued at $119,000. Bailard Inc. acquired a new position in Bioventus during the 4th quarter worth $307,000. Citigroup Inc. increased its holdings in Bioventus by 13,474.4% during the 3rd quarter. Citigroup Inc. now owns 52,533 shares of the company’s stock worth $173,000 after purchasing an additional 52,146 shares during the period. Finally, GSG Advisors LLC raised its position in Bioventus by 55.8% in the 1st quarter. GSG Advisors LLC now owns 26,511 shares of the company’s stock valued at $133,000 after purchasing an additional 9,500 shares in the last quarter. Hedge funds and other institutional investors own 62.94% of the company’s stock.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.